The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

NCI Trials

NCI Trials for October

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – ABTC-1804

Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas

Adult Brain Tumor Consortium

Grossman, Stuart Alan

(410) 955-8837

Phase II – ACNS1723

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Children’s Oncology Group

Lulla, Rishi Ramesh

(401) 444-5171

Phase III – A221803

Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial

Alliance for Clinical Trials in Oncology

Corbin, Kimberly S.

(507) 284-2669

Phase Other – WF-1805CD

Implementation and Effectiveness Trial of HN-STAR

Wake Forest NCORP Research Base

Weaver, Kathryn E.

(336) 713-5062

Table of Contents

YOU MAY BE INTERESTED IN

Capitol Hill

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.
By Claire Marie Porter
Guest Editorial

Building cancer care resilience through international observerships: Lessons from Ukraine

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

By Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Y. Poylin, Rostyslav Semikov, Arman Kacharian, Douglas Davis, Nataliya Uboha, Natalka Suchowerska, Viktor Iakovenko, Jacqueline Hart, Mark Poznansky, Darya Kizub and Nelya Melnitchouk
ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account